Low-risk group (0 points), Intermediate-1 group (0.5~1.0 points), Intermediate-2 group (1.5~2.0 points), High-risk group (≥2.5 points).

The IPSS is based on FAB classification and can assess the natural course of the disease in patients, which is significant for prognostic evaluation and treatment guidance. For low-risk and intermediate-1 MDS, hematopoietic stimulation, differentiation induction, biological response modifiers, and supportive therapy should be used primarily to improve quality of life; for intermediate-2 and high-risk MDS, combined chemotherapy regimens for AML (Acute Myeloid Leukemia) and hematopoietic stem cell transplantation (HSCT) should be employed to achieve disease remission and improve survival rates.